Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian biotech Unnatural Products to hunt down “undruggable” targets.

Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets David Baker’s Nobel Prize-winning lab has successfully designed high affinity binders to disordered proteins, expanding ...

One of targeted protein degradation’s main draws is the path it offers to reach “undruggable” targets. An estimated 85% of human proteins can’t be effectively targeted by typical small ...

New AI-assisted methods take aim at ‘undruggable’ proteins Intrinsically disordered proteins have been historically difficult to target by Sarah Braner July 18, 2025 3 min read ...

A world-first clinical trial targeting cancers that are currently undruggable will begin later this year, led by a research team from The Australian National University (ANU) and Canberra Health ...

Optimizing Stability of Engineered Anti-RAS bioPROTAC for Rapid Degradation of Undruggable Proteins Thursday, June 5, 2025 11:00 AM-1:00 PM BIOMED Master's Thesis Defense Title: Optimizing Stability ...